Non-viral Suicide Gene Therapy: Cytosine Deaminase Gene Directed by VEGF Promoter and 5-fluorocytosine as a Gene Directed Enzyme/prodrug System in Breast Cancer Model

Abstract

The present study investigated the potential of vascular endothelial growth factor (VEGF) promoter to derive cytosine deaminase (CD) transfected by polyamidoamine (G4-PAMAM) dendrimers to 4T1 murine breast cancer cell line as gene-directed enzyme/prodrug therapy. The VEGF promoter and cytosine deaminase gene were cloned into the pEGFP-N1vector from the genomic DNA of 4T1 and E. coli, respectively. The frequency of transfection for VEGF-CD-pEGFP-N1 and pEGFP-N1- CD treated groups was 35±3 and 36±4, respectively. MTT assay was perform to evaluate the cytotoxic effects of converted 5-flurocytosine on 4T1 cells. Also, the optimal concentration of 5-FC in 4T1 cells transfected by VEGF-CD-pEGFP-N1 plasmid was evaluated. The GFP expression of transfected 4T1 cells by VEGF-CD-pEGFP-N1were observed by fluorescent microscopy and flowcytometry. Results demonstrated that the suicide CD gene was successfully expressed in 4T1 cells determined by RT-PCR and GFP expression. A concentration of 200 μg/ml 5-FC was identified as optimal dose of prodrug. Furthermore, the CD/5-FC enzyme/prodrug system not only demonstrated toxicity on transformed 4T1 cells but also exerted a ‘bystander effect’ determined by MTT assay. The results showed that by 35% transfection with VEGF-CD–pEGFP-N1and CD-pEGFP-N1 plasmids, 80% and 90% inhibition of the cells growth occurred, respectively.

Key words

PAMAM dendrimer - Suicide gene therapy - Cytosine deaminase - Gene delivery - VEGF promoter - 5-Fluorocytosine

Publication History

Received: 31 March 2021

Accepted: 20 April 2021

Article published online:
28 June 2021

• References

• 1 Duarte S. et al. Suicide gene therapy in cancer: where do we stand now? . Cancer letters 2012; 324 p 160-170
• 2 Karantza V. Keratins in health and cancer: more than mere epithelial cell markers . Oncogene 2011; 30 p 127-138
• 3 Malecki M. Frontiers in suicide gene therapy of cancer . Journal of genetic syndrome & gene therapy. 2012: 2012
• 4 Ruegg C, Mutter N. Anti-angiogenic therapies in cancer: achievements and open questions . Bulletin du cancer 2007; 94 p 753-762
• 5 Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses . Science 2004; 305 p 200-205
• 6 Noguchi T. et al. miRNA-503 promotes tumor progression and is associated with early recurrence and poor prognosis in human colorectal cancer . Oncology 2016; 90 p 221-231
• 7 Herr R, Brummer T. BRAF inhibitors in colorectal cancer: toward a differentiation therapy? . Molecular & cellular oncology 2015; 2 p e1002709
• 8 Weber WA, Morris MJ. Molecular imaging and targeted radionuclide therapy of prostate cancer . Journal of Nuclear Medicine 2016; 57 p 3S-5S
• 9 Lv Q. et al. Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer . International journal of molecular sciences 2016; 17 p 2095
• 10 González-Cao M. et al. Targeting PD-1/PD-L1 in lung cancer: current perspectives . Lung Cancer 2015; 6 p 55
• 11 Cheng Y. et al. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives . Chemical Society Reviews 2011; 40 p 2673-2703
• 12 Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: a tutorial . Chemical Society Reviews 2011; 40 p 173-190
• 13 Morgan RA. Live and let die: a new suicide gene therapy moves to the clinic . Molecular Therapy 2012; 20 p 11-13
• 14 Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells . Advanced drug delivery reviews 2005; 57 p 733-753
• 15 Ramamoorth M, Narvekar A. Non viral vectors in gene therapy-an overview . Journal of clinical and diagnostic research: JCDR 2015; 9 p GE01
• 16 Wirth T, Ylä-Herttuala S. Gene therapy used in cancer treatment . Biomedicines 2014; 2 p 149-162
• 17 Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer . The Journal of clinical investigation 2000; 105 p 1169-1172
• 18 Gopinath P, Ghosh SS. Monitoring green fluorescent protein for functional delivery of E. coli cytosine deaminase suicide gene and the effect of curcumin in vitro . Gene Ther Mol Biol 2007; 11 p 219-228
• 19 Springer CJ, Niculescu-Duvaz I. Patent property of suicide gene therapy involving prodrugs 1996-1999 . Expert Opinion on Therapeutic Patents 1999; 9 p 1381-1388
• 20 Akbulut H. et al. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon . Cancer Gene Therapy 2003; 10 p 388-395
• 21 Ireton GC, Black ME, Stoddard BL. The 1.14 Å crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy . Structure 2003; 11 p 961-972
• 22 Liu Y. et al. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy . Cancer gene therapy 2006; 13 p 346-356
• 23 Freeman SM. et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified . Cancer research 1993; 53 p 5274-5283
• 24 Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system . Proceedings of the National Academy of Sciences 1992; 89 p 33-37
• 25 Fischer U. et al. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells . Oncogene 2005; 24 p 1231-1243
• 26 Negroni L. et al. Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90β phosphorylation . Molecular cancer therapeutics 2007; 6 p 2747-2756
• 27 Kanai F. et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil . Cancer research 1998; 58 p 1946-1951
• 28 Cramer F. et al. Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines . Cancer gene therapy 2012; 19 p 675-683
• 29 Ostertag D. et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector . Neuro-oncology 2011; 14 p 145-159
• 30 Kaliberov SA, Buchsbaum DJ. Cancer treatment with gene therapy and radiation therapy . Advances in cancer research 2012; 115 p 221-263
• 31 Sterman DH. et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-β gene transfer for mesothelioma and metastatic pleural effusions . Molecular Therapy 2010; 18 p 852-860
• 32 Zarogoulidis P. et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review . Cancer gene therapy 2012; 19 p 593-600
• 33 Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis . Advanced drug delivery reviews 2009; 61 p 554-571
• 34 Karjoo Diarkhan Z. Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells. 2015 Rutgers University-Graduate School-New Brunswick.
• 35 Kurayoshi K. et al. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs . Biochemical and biophysical research communications 2014; 450 p 240-246
• 36 Kia A. et al. Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression . Molecular cancer therapeutics 2012; 11 p 2566-2577
• 37 Zhu ZB. et al. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter . Gene therapy 2004; 11 p 645-648
• 38 Chen X, Godbey W. The potential of the human osteopontin promoter and single-nucleotide polymorphisms for targeted cancer gene therapy . Current gene therapy 2015; 15 p 82-92
• 39 Nemunaitis J. et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors . Molecular Therapy 2010; 18 p 429-434
• 40 Konecny GE. et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients . Clinical cancer research 2004; 10 p 1706-1716
• 41 Abbaspour A, Esmaeilzadeh A, Sharafi A. Suicide gene therapy-mediated purine nucleoside phosphorylase/fludarabine system for in vitro breast cancer model with emphasis on evaluation of vascular endothelial growth factor promoter efficacy . 3 Biotech 2021; 11 p 1-14
• 42 Lappalainen K. et al. Comparison of cell proliferation and toxicity assays using two cationic liposomes . Pharmaceutical research 1994; 11 p 1127-1131
• 43 Zhang B. et al. An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma . PloS one 2018; 13 p e0196686
• 44 Ichikawa T. et al. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus . Cancer gene therapy 2000; 7 p 74-82
• 45 Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress . The AAPS journal 2009; 11 p 671-681
• 46 Karjoo Z, Chen X, Hatefi A. Progress and problems with the use of suicide genes for targeted cancer therapy . Advanced drug delivery reviews 2016; 99 p 113-128
• 47 Malekshah OM. et al. Enzyme/prodrug systems for cancer gene therapy . Current pharmacology reports 2016; 2 p 299-308
• 48 Chaszczewska-Markowska M. et al. Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase–for colorectal cancer . Cancer letters 2008; 262 p 164-172
• 49 Kilstrup M. et al. Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli . Journal of bacteriology 1989; 171 p 2124-2127
• 50 Mandal S, Tiwari PK. Gene Therapy and Gene Editing for Cancer Therapeutics, in Handbook of Research on Advancements in Cancer Therapeutics . 2021; IGI Global p 116-204
• 51 Zhao Y. et al. Gemcitabine resistance in triple‑negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol . Oncology letters 2020; 20 p 1-1